On Tuesday, the Advanced Research Projects Agency for Health (ARPA-H) held a day-long gathering related to its ibogaine funding opportunity, dubbed Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder (ASCENT-IBO, for short). That opportunity is outlined in a Special Notice issued by the agency, with proposals due October 15th.

Source

Previous articlePα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Next articleWhat Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics